NCT06951802 Endometriosis and Pain Treatment by Intraoperative Administration of Low-dose Ketamine
| NCT ID | NCT06951802 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Condition | Endometriosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 118 participants |
| Start Date | 2024-12-03 |
| Primary Completion | 2025-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 118 participants in total. It began in 2024-12-03 with a primary completion date of 2025-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
RCT comparing intraoperative administration of low-dose ketamine during laparoscopic endometriosis operation and the postoperative pain outcome
Eligibility Criteria
Inclusion Criteria: * Patients undergoing surgery for endometriosis operation requiring general anaesthesia at the Inselspital, Bern University Hospital, University of Bern, Department of gynaecology and obstetrics. * Age ≥ 18 years * American Society of Anesthesiologist (ASA) physical status 1-3 * Patients with known or suspected endometriosis * Written informed consent. Exclusion Criteria: * Age \< 18 years * ASA physical status ≥4 * Higher-grade atrioventricular block without pacemaker * Severe hypovolemia or bradycardia * Uncontrolled hyper- or hypotension * Liver disease * Known malignant hyperthermia * Cardiovascular instability or severe heart failure (New York Heart Association classification (NYHA) \> III) * Myocardial infarction during the last 30 days prior to surgery * Increased intracranial or increased intraocular pressure * Limited peripheral autonomic activity, hypersensitivity to ketamine or propofol or its components * Pregnancy * Rejection or lack of consent of the patient or relatives
Contact & Investigator
Christian Vetter, MD
STUDY CHAIR
Dep. of Anaesthesiology and Pain Medicine, Inselsptial Bern
Frequently Asked Questions
Who can join the NCT06951802 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Endometriosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06951802 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06951802 currently recruiting?
Yes, NCT06951802 is actively recruiting participants. Contact the research team at christian.vetter@insel.ch for enrollment information.
Where is the NCT06951802 trial being conducted?
This trial is being conducted at Bern, Switzerland.
Who is sponsoring the NCT06951802 clinical trial?
NCT06951802 is sponsored by Insel Gruppe AG, University Hospital Bern. The principal investigator is Christian Vetter, MD at Dep. of Anaesthesiology and Pain Medicine, Inselsptial Bern. The trial plans to enroll 118 participants.